Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseasePaul M. Ridker, Robert J. Glynn, Christie M. Ballantyne et al.|New England Journal of Medicine|2017Cited by 9.1k
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trialPaul M. Ridker, Hakan Kültürsay, Jean MacFadyen et al.|The Lancet|2017Cited by 1.3k